BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37429175)

  • 1. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surgical therapy of hepatic fibrolamellar carcinoma].
    Meriggi F; Forni E
    Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma.
    Rosa M; Mohammadi A
    Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
    Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
    J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
    Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma.
    Anysz-Grodzicka A; Podgorska J; Cieszanowski A
    Curr Med Imaging Rev; 2019; 15(3):269-280. PubMed ID: 31989878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
    Abdelhamed W; El-Kassas M
    World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrolamellar Carcinoma: What Is New and Why It Matters.
    Graham RP
    Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of the clinicopathologic features of fibrolamellar carcinoma.
    Torbenson M
    Adv Anat Pathol; 2007 May; 14(3):217-23. PubMed ID: 17452818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.
    Mayo SC; Mavros MN; Nathan H; Cosgrove D; Herman JM; Kamel I; Anders RA; Pawlik TM
    J Am Coll Surg; 2014 Feb; 218(2):196-205. PubMed ID: 24315886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation.
    McLarney JK; Rucker PT; Bender GN; Goodman ZD; Kashitani N; Ros PR
    Radiographics; 1999; 19(2):453-71. PubMed ID: 10194790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrolamellar Carcinoma: A Concise Review.
    Lin CC; Yang HM
    Arch Pathol Lab Med; 2018 Sep; 142(9):1141-1145. PubMed ID: 30141990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.